PRZO:NASDAQParaZero Technologies Ltd. Analysis
Data as of 2026-04-26 - not real-time
$0.72
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its short‑term, mid‑term and long‑term moving averages, confirming a bearish price bias despite a modest bullish signal from the MACD histogram and an increasing volume trend. RSI sits in a neutral zone, while beta and 30‑day volatility are markedly high, and the historical maximum drawdown exceeds half of the price range, underscoring pronounced price instability.
Fundamentally, the company reports negative operating margins, a sizable cash burn and a price‑to‑book multiple that dwarfs typical industry levels, indicating an overvalued valuation profile. Nevertheless, a recent follow‑on purchase order for its counter‑drone system from an Israeli defense entity provides a tangible growth catalyst, though the absence of earnings, dividend and a thin market cap keep the risk profile elevated.
Fundamentally, the company reports negative operating margins, a sizable cash burn and a price‑to‑book multiple that dwarfs typical industry levels, indicating an overvalued valuation profile. Nevertheless, a recent follow‑on purchase order for its counter‑drone system from an Israeli defense entity provides a tangible growth catalyst, though the absence of earnings, dividend and a thin market cap keep the risk profile elevated.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price below all moving averages reinforcing bearish momentum
- Negative operating cash flow and ongoing cash burn
- Elevated volatility and beta amplifying price swings
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Follow‑on defense order adds near‑term revenue visibility
- Technical MACD crossover suggests a tentative upside
- Continued earnings deficits and high PB ratio limit upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic niche in counter‑UAS solutions with expanding defense demand
- Potential market penetration beyond Israel into U.S. and EU customers
- Low share float and thin market cap could reward successful execution
Key Metrics & Analysis
Financial Health
Revenue Growth6.00%
ROE-380.47%
ROA-85.43%
Debt/Equity9.71
P/B Ratio4.5
Op. Cash Flow$-5804052
Free Cash Flow$-3259947
Industry P/E31.1
Technical Analysis
TrendBearish
RSI40.5
Support$0.66
Resistance$0.85
MA 20$0.74
MA 50$0.97
MA 200$1.31
MACDBullish
VolumeIncreasing
Fear & Greed Index88.02
Valuation
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.77
Volatility103.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.